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Chagas disease
Chagas disease is the clinical condition triggered by infection with the protozoan Trypanosoma cruzi. The infection is transmitted by triatomine insects while blood feeding on a human host. Field studies predict that one third of an estimated 18 million T cruzi-infected humans in Latin America will die of Chagas disease. Acute infections are usually asymptomatic, but the ensuing chronic T cruzi infections have been associated with high ratios of morbidity and mortality: Chagas heart disease leads to unexpected death in 37.5% of patients, 58% develop heart failure and die and megacolon or megaoesophagus has been associated with death in 4.5%. The pathogenesis of Chagas disease appears to be related to a parasiteinduced mutation of the vertebrate genome. Currently, treatment is unsatisfactory.
A merican trypanosomiasis is an enzootic infection caused by the kinetoplastid flagellate Trypanosoma cruzi. The spread of the enzootics coincides with the distribution of the triatomine vectors from parallel 42˚N in the southern US to 42˚S in Patagonia, Argentina. 1 Fossil remnants have suggested that humans arrived on the American continent about 50 000 years ago. It may be supposed that the triatomines involved in the life-cycle of T cruzi, eventually transmitted the infection to Amerindians approximately 9000 years ago, probably when triatomines adapted to human dwellings in Chile and Peru, adjacent to the Atacama desert. 2 Paleoparasitological studies showed that 97 (40.6%) of 238 mummies yielded molecular data consistent with T cruzi infection. It is reasonable to suppose that American trypanosomiasis was a serious burden to Amerindians in pre-Columbian days. It is now known that T cruzi infection was readily transmitted to European and African settlers living close to triatomine wild-life ecotopes in the American continents.
Chagas disease is the clinical condition associated with T cruzi infection, described in the pioneering work of Dr Carlos Chagas, a Brazilian physician who worked at the Oswaldo Cruz Institute, Rio de Janeiro. 3 He described the dividing epimastigote and the metacyclic trypomastigote forms of T cruzi in the fore-gut and the hind-gut, respectively, of a Panstrongylus megistus captured in a human hut in the hinterland of Minas Gerais State, Brazil, in 1909. Next, he reported that he had found trypomastigotes in the blood of a mammal, a domestic cat.
Serendipitously, he investigated a 1-year-old child with fever of unknown origin and showed T cruzi trypomastigotes in a peripheral blood smear by direct microscopic examination. 4 
T CRUZI COLONISATION OF THE HUMAN BODY Insect vectors of T cruzi infection
At least 40 triatomine species can harbour T cruzi, thus they are all potential transmitters of infection. 5 The Triatoma sp, which adapted to the rural peri-domicile areas and domiciles of dry ecosystems of Central and South America, 6 are the main transmitters of the infection ( fig 1A, B) . These species have been implicated in 10-12 million cases of Chagas disease in humans. Next in epidemiological importance are the Rhodnius sp, dwelling in humid tropical climates, and the ubiquitous Panstrongylus sp. 1 5 After having a blood meal, the triatomine becomes engorged and the infective metacyclic trypomastigotes are passed in the faeces. The parasitic form enters the body when the individual scratches the skin wound inflicted by the insect's mouth-part, or it may enter the body through permissive mucosa or conjunctival membranes. On entry into the body, the trypomastigotes (fig 2) that invade tissue histiocytes survive the acidic parasitophorous vacuoles and leave the hostile environment to freely enter the host-cell cytoplasm. The port of entry of the infection in the skin or in the eye conjunctiva is clinically seen as an indurate, chronic inflammatory process typical of a delayed-type hypersensitivity reaction. The flagellates round up into amastigotes that undergo many cycles of multiplication by binary fission. The cell fills with amastigotes (fig 3) , which will differentiate into mobile trypomastigotes (fig 4) that burst out reaching the blood stream ready to infect other cells of the body. Early papers have shown a direct relationship between host cell membrane receptor density and parasite load in tissues. 7 8 In fact, every cell in the human body with the exception of neurones could be affected by T cruzi colonisation in vivo. T cruzi infection persists in the human body for life.
Blood transfusion
T cruzi infection can be readily transmitted by blood transfusion. 9 10 The migration of people infected by T cruzi poses a threat to those countries where this insect-transmitted disease does not occur. Chagas disease has become a potential problem associated with migration from endemic areas to the US, Canada, Eastern Europe, Australia and Japan. 11 be seropositive in Brooklyn and Queens in New York City (CA Santos-Buch, unpublished observation), and a similar proportion was found among Nicaraguan immigrants in Washington, DC. 12 Appropriate selection of blood donors, the use of sensitive screening tests and the application of a mandatory quality assurance system have maintained the safety of blood banks in most Latin American countries. 13 The addition of cresyl violet to donor blood while in storage in Buenos Aires blood banks was effective in preventing the transmission of T cruzi. The prevention of transfusionassociated protozoan infections depends mainly on selection of donors.
14 Additionally, the use of more sensitive and accurate advanced molecular diagnostic tests has greatly reduced the risk of acquisition of blood-borne Chagas disease. 15 Congenital transmission of T cruzi has been reported in Latin American countries where Chagas disease is prevalent in those of reproductive age. Congenital transmission ranges from 2.5% 16 in northeastern Brazil to 9.5% in Bolivia. 17 Additionally, T cruzi can be transmitted by organ transplant, by laboratory accidents and by accidental self-inoculation by hospital personel.
Diagnosis
Direct demonstration of the parasite in a living mammalian host can be achieved only in the acute phase, by microscopic observation of a fresh blood smear having the motile parasites amid red cells. Chronic infections require diagnostic procedures that rely on parasite amplification before they can be detected by microscopy. Xenodiagnosis consists of allowing a parasite-free triatomine to have a blood meal from the clinically suspected candidate and examining the bug's excrements 30 and 60 days later for the presence of the parasite. 18 A parallel diagnostic attempt can be made by inoculating citrate-treated blood in axenic culture medium followed by a microscopic search for the parasite at set times. The sensitivity of both methods varies with the ability of a low number of parasites to multiply in fresh medium and requires long periods of time. The immediate detection of chronic Chagas disease relies on the indirect demonstration of specific anti-T cruzi antibodies in patient serum or on nucleic acid-based tests. 18 High-fidelity tests 19 20 to detect specific antibodies include indirect haemagglutination, indirect immunofluorescence and the enzyme-linked immunosorbant assay. The sensitivity of individual tests ranges from 96.5% to 100% and their specificity from 87% to 98.9%. However, cross-reactive antibodies to T cruzi-specific antigens can be present in the serum of some patients with other kinetoplastid infections, with some intracellular parasite or bacterial diseases (eg, malaria, toxoplasmosis, paracoccidioidomycosis, tuberculosis, leprosy, syphilis and pemphygus) and with some autoimmune conditions (eg, rheumatoid arthritis, systemic lupus erythematosus, etc), albeit at much low titres. 21 22 Differential diagnosis can be achieved by immunoblot assays. 23 Diagnoses can be confirmed by the use of nucleic acid tests such as polymerase chain reaction amplification with specific primer sets followed by hybridisation with internal probes. [24] [25] [26] In view of the major caveats leading to false-negatives and false-positives, it has been agreed that at least two immunological tests are required to confirm a diagnosis of Chagas disease. 20 27 Epidemiology and control The unquestionable benefits of major insecticide-based control programmes 28 showing abrupt drops of T cruzi infection in young populations need to be emphasised. It is expected that reported success will be reflected in low death rates three decades after dislodgment of domestic Triatoma infestans. The progress achieved thus far provides a window of opportunity before the triatomine develops resistance to the widespread and indiscriminate use of pyrethroid insecticides. 29 More measures for control aimed at a sustainable reduction in prevalence of Chagas disease in the tropical rainforest ecosystems of Central and South America have been envisaged [30] [31] [32] [33] . Above all, control cannot be satisfactorily achieved by means other than social development and improvement of human living conditions. Particularly, interventions to prevent infection by T cruzi and improve children's health mean poor housing has to be improved. 34 However, given the large pool of primary hosts for this enzootic disease, complete control of T cruzi arthropod vector transmission to the human population seems daunting. Demographic change in Latin America has been marked over the past four decades. For example, in the 1960s, 75% of the population lived in rural areas, whereas at present 81% live in metropolitan areas. As a consequence of the rural exodus, millions of people with Chagas disease live in the largest cities. 35 The rural exodus appears to be related to the migration of people with Chagas disease to the cities for jobs and education, and thus the disease has spread to more socioeconomic classes. The spread of Chagas disease in urban areas needs to be reviewed separately on the basis of active vector-transmitted T cruzi infection in populations inhabiting the outskirts of major cities in many Latin American countries. [36] [37] [38] [39] [40] Furthermore, localised transmission of acute Chagas disease has been associated with the oral route of contamination. [41] [42] [43] [44] [45] Overall, Chagas disease in urban areas has been associated directly with about 1 death in 10 among people aged between 25 and 64 years. 46 Effective prophylaxis against T cruzi appears to be a formidable task as there are elusive biological challenges. An effective immunoprophylaxis against intracellular infection is unattainable because specific, concomitant, steadystate immunity poses a somewhat effective barrier against parasite circulation in the blood, but does not eliminate parasites that colonise non-phagocytic muscle cells, allowing the protozoa to persist throughout its host's life. 1 Thus, vaccination against Chagas disease is not feasible with the currently available biotechnologies. 9 29 On the other hand, chemotherapy for T cruzi infection may be ideal because it would curtail parasitism in reservoir hosts, diminishing peridomestic insect vector dissemination. Anti-trypanosome nitroderivatives that suppress blood parasitism show severe toxicity, requiring careful prescription. 27 47-53 T cruzi infections occur in a circumscribed region of the world that represents a relatively small market. Accordingly, pharmaceutical companies have been reluctant to invest resources for the development of vaccines and drugs to control and treat Chagas disease.
CLINICAL MANIFESTATIONS Acute Chagas disease
Acute cases of Chagas disease are characterised by the presence of the parasite in the patient's blood, thus allowing the demonstration of T cruzi trypomastigotes by direct microscopic examination of a fresh blood smear. Often, the acute phase of the infection is not perceived by the patient; 95% of the cases are asymptomatic. In the remaining symptomatic cases, the clinical manifestations of acute Chagas disease are fever, malaise, muscle and joint pains, somnolence, cramps and diarrhoea, oedema, respiratory disturbances, cyanosis and comma. Considering that ,5% of patients with acute symptoms die, 54 it can be estimated that mortality in this phase of the infection is between 1:2500 and 1:5000. Death in the acute phase of the disease is caused by myocarditis or meningoencephalitis, with attendant complications such as bronchopneumonia. 55 The acute phase of T cruzi infection usually goes into remission spontaneously and the infection enters the chronic stage within 3-4 months of its onset.
Chronic Chagas disease
Acute cases with or without symptoms of T cruzi infection lead to the chronic stages, which can present in any age group. 56 Interestingly, two thirds of 18 million people harbouring chronic T cruzi infection do not show any detectable clinical manifestation of Chagas disease. People considered to be in the indeterminate chronic phase of the infection do not die of Chagas disease. About one third of the chronically infected human population develop clinical manifestations of the disease. 56 The symptomatic disease affects the heart in 94.5% of cases; these patients are considered to have chronic Chagas heart disease. Heart insufficiency is related to the cause of death in 58% of patients, whereas arrhythmias have been associated with unexpected deaths in 36.5%. The remaining 4.5% of patients with chronic Chagas infection show mega syndromes, a disease state that involves the oesophagus (megaoesophagus) and the colon (megacolon). 57 Chronic Chagas heart disease affects both sexes equally, frequently at between 30 and 45 years of age. In the group of patients showing progressive changes on electrocardiogram, unexpected death can occur in 37.5% of cases. Importantly, 58% of the patients with chronic Chagas heart disease show ominous signs of heart insufficiency and frequently die 7 months to 2 years after the onset of symptoms. 56 People with Chagas disease with cardiac or gastrointestinal manifestations of the disease may also show widespread lesions involving the sympathetic and parasympathetic peripheral nervous systems. These chagasic nervous system lesions specifically explain the physiopathological condition of the heart and the mega syndromes observed at the bedside. 58 59 Chagas disease and AIDS The natural course of T cruzi infection can be modified by coinfections. Chagas disease and HIV mutually affect each other. 60 HIV infection may lead to reactivation of T cruzi infection. 61 The disease in some T cruzi-HIV-infected patients may have a long silent clinical course, whereas in others it may present with meningoencephalitis or myocarditis.
Therefore, these coinfections should be investigated in endemic and non-endemic regions of the world. 62 
PATHOGENESIS
Two theories have been set forth to explain the pathogenesis of the lesions in Chagas disease. The parasite persistence theory postulates that Chagas lesions could be a direct consequence of the mechanical rupture of the parasitised host cell and subsequent inflammation. The autoimmune theory ascribes Chagas lesions to the rejection of parasite-free target cells by immune lymphocytes. Here we present data showing that these theories are not mutually exclusive.
Parasite persistence
Most observers agree that parasite persistence in the human host may lead to the rupture of colonised cells in the acute phase of the infection. The microscopic finding of parasitefree target cell lyses by immune effector lymphocytes has cast doubt on whether mechanical rupture is the main feature of the pathogenesis of acute disease. The difficulty in establishing a direct relationship between the intracellular presence of parasitic T cruzi forms and concomitant tissue destruction can be clearly shown in endemic areas of Chagas disease, where approximately one third of the infected human population succumb to Chagas disease. Moreover, 80% of patients with Chagas disease who died of the disease did not show amastigote nests of the parasite in histopathological sections of the heart. Furthermore, a lack of physical proximity between the parasite nest and the inflammatory lesions was clearly shown among chronic Chagas hearts with intracellular amastigotes. There are, however, several questions that remain unanswered: (1) Why are acute infections usually asymptomatic and remit spontaneously? (2) If severe pathology is present in every patient with Chagas disease, is it also present in the cryptic T cruzi infection? (3) Why do patients with cryptic T cruzi infection have high rates of morbidity and mortality?
Answers to these questions have been sought in longitudinal field studies-for example, among 190 adults positive for antibody tests for T cruzi infection, 56 patients had parasitaemias detected by xenodiagnoses, but the remaining 134 patients with Chagas disease did not. In this series, progressive Chagas heart lesions were shown in 30% of the patients with detected parasitaemias, but in 28.8% of the patients there was no detectable parasitaemia. 63 These findings have suggested that the severity of heart lesions and the evolution of the disease may not be associated with the prevalence of parasitaemias in patients with chronic Chagas disease.
Autoimmunity
Experimental data have shown that autoimmunity is an important component of the pathogenesis of Chagas disease. 64 The observed rejection of target heart fibres by the 5) appears to favour autoimmunity. The accelerated rejection of embryonic rabbit cells by immune lymphocytes derived from chronically T cruzi-infected rabbits has been considered evidence of autoimmunity in Chagas disease. 64 65 Immune factors and possible mechanisms triggering the lesions of Chagas disease have stirred discussions on the role of T cruzi antigens in the pathogenesis of the disease, such as crossreactivity and molecular mimicry. 66 A lot more information on this subject can be found in previous review papers. 67 68 We believe that the roles played by parasite persistence in the body and by autoimmunity are essential to the pathogenesis of Chagas disease.
The observation of progressive Chagas heart disease in T cruzi-infected rabbits that had been treated with antitrypanosome nitroderivatives generated an unavoidable question: what could be sustaining those destructive lesions in the heart cells of treated rabbits? We sought an answer to this question by examining the hypothesis that horizontal DNA transfer from the parasite to the mammal host (a mutation) may explain the autoimmune lesions of Chagas disease.
HORIZONTAL DNA TRANSFER
Horizontal transfer of T cruzi kinetoplast DNA (kDNA) minicircles to the genome of mammal hosts has been detected. [68] [69] [70] [71] [72] Furthermore, a truncated kDNA sequence was found in the genome of a T cruzi-infected baboon (Papyo hamadryas), which flanked the host DNA (GenBank accession number DQ241812). Southern blots of genomic DNA from the heart, skeletal muscle and intestine of a chronic Chagas rabbit hybridised with a kDNA probe. Interestingly, the 2.2 kb kDNA band formed with the rabbit genome DNA showed a configuration different from the typical 1.4 kb band formed with the parasite DNA. These specific bands did not hybridise with other parasite nuclear DNA internal probes. 25 73 The sequencing showed that both ends of the kDNA were flanked by rabbit DNA (GenBank accession numbers AF400668, AF399841 and AF415293) and that the kDNA integrated in direct CACCAACC repeats within the rabbit genome. The host DNA, flanking the kDNA, showed homology with the clone LBNL-125D4, which is a LINE-1 retrotransposon, loaded with short SINE repeats interspersed in the vertebrate genome. 74 An open reading frame that began in the rabbit DNA extended into the integrated kDNA. DataBank analysis revealed a transcript potentially coding the chimera antigen r45 (GenBank accession number AAR24603.1). These observations have suggested that persisting T cruzi infections can be a cumulative source of parasite-induced kDNA mutations. We suggest that the newly formed open reading frames translating chimera proteins trigger the pathology of Chagas disease.
kDNA INHERITANCE
When germ cells of an 18-month-old boy were found colonised by T cruzi amastigotes, we predicted that the parasite could invade stem cells (ARL Teixeira, unpublished observation). The permissiveness of stem cell lines to T cruzi infection was an indication that genital crest cells could acquire kDNA mutations during the differentiation stage from the 4th to the 8th day of gestation. In fact, kDNA integration in the offspring of chronically T cruzi-infected rabbits was shown. Genomic DNA extracted from various body tissues showed that the experimental animals were only kDNA positive by nucleic acid tests. The cloning and sequencing of kDNA-positive samples showed minicircle sequences integrated in the genome of the rabbits (GenBank accession numbers AY488498-AY488503). To determine whether a live infection is required for integration, kDNA minicircle sequences were inoculated intravenously in T cruzi-infected rabbits. Minicircle sequences were polymerase chain reaction amplified only during the following 3 weeks, thus showing that living infection is required for sustained vertical transfers of kDNA mutations. Hallmark chagasic histopathological condition (minimal rejection units) was found in the heart, skeletal muscles and parasympathetic nervous system of the offspring. In the control group, no lesions were found in the tissues of kDNAnegative rabbit offspring.
Birds are refractory to T cruzi infection, 1 and thus represent a ''clean'' model to study the vertical transfer of kDNA mutations. Therefore, experiments were conducted in Gallus gallus because T cruzi infections could be established early in embryonic life. kDNA mutations were shown to be present in 24% of the chickens which hatched from T cruzi-infected eggs. The mutated chickens yielded sperm and unfertile ova, whose DNA contained kDNA amplification products. Crossing of kDNA-positive hens with roosters resulted in kDNA-mutated chickens in all instances. Sequencing showed integration of kDNA in a retrotransposon (CR-1) at chromosome 4 (GenBank accession number AY237306). Interestingly, some growing kDNA-positive chickens developed muscle weakness whereas others showed signs of heart failure. When these birds died, they showed the typical minimal rejection units of Chagas disease found in rabbits and in humans. The results therefore strongly suggest that the pathology observed in FO, F1 and F2 kDNA-mutated birds is parasite-independent. Typically, the lesions in the heart (fig 5) , skeletal muscle and the parasympathetic ganglia (fig 6) of kDNA-mutated birds were comprised of minimal rejection unit lesions (fig 7) with features similar to those seen in the human host. We believe that kDNA integration in the vertebrate-host genome has the potential to trigger an autoimmune response that results in host-tissue lesions, and explains the pathogenesis and variable clinical manifestations of Chagas disease. 1 
HISTOPATHOLOGICAL STUDY
Acute Chagas disease T cruzi can parasitise any nucleated cell in the human body. Therefore, connective tissue, striated and smooth muscles, germinal cells, and phagocytic mononuclear cells can be intensely parasitised. Also, epithelial cells of the liver, kidneys, thyroid, pancreas and skin are permissive to T cruzi. Schwann cells of the peripheral nerve fibres, ganglia and glial cells (usually astrocytes) of the brain are parasitised, but neurones are spared. Often, amastigote parasitic forms that colonise muscle cells become inaccessible to the immune system effector cells and, therefore, can hibernate in those niches for an unknown period of time. Grossly, the heart in humans with acute disease increases in size and becomes dilated, flabby and congested. The lymph nodes near the emergence of the aorta and the pulmonary artery become engorged. In the epicardial surface, the coronary and the lymphatic vessels are dilated. These gross findings predict the presence of intense inflammatory infiltrates in the heart. Microscopically, muscle fibres and occasionally histiocytes show pseudocysts (cysts without a wall) formed by intracellular T cruzi amastigotes. However, a conspicuous finding in the acute phase of the infection is that of inflammatory mononuclear cell infiltrates and parasite-free host cell lyses (fig 8) . These inflammatory cells, mainly macrophages and activated lymphocytes, invade muscle structures and the parasympathetic and sympathetic ganglia in the body. The lysis of parasite-free neurones is associated with adherence of the immune system mononuclear cells to the target cell outer plasma membrane. Electron microscopic studies of tissue lesions have shown inflammatory infiltrates in association with glial cell elements. Heart cell destruction by immune lymphocytes and depopulation of the neurones are hallmarks of the pathology of acute-phase Chagas disease. Although the pathology of the acute phase shows the presence of scattered parasites in the heart and nervous system, its main components are the inflammatory infiltrates and target-cell lyses. Sometimes the immune system mononuclear cells palisade the perforating meningeal blood vessels in VirchowRobin spaces. In the brain, T cruzi amastigotes are more frequently found in astrocytes. These lesions are characteristic of meningoencephalitis.
Indeterminate phase
During the indeterminate phase of chronic T cruzi infections, patients do not show clinic manifestations related to heart or digestive tract lesions. 75 People who were in the indeterminate phase of the infection and died of fatal accidents had no heart lesions or megaoesophagus or megacolon. Nonetheless, the indeterminate phase of the infection was established by the direct demonstration of the parasite or by phenotype and genotype markers of the cryptic infection. Microscopically, biopsies of 20 patients with these cryptic infections showed discrete, very low intensity inflammatory heart lesions. 76 
Chronic Chagas disease
The size of the heart of a patient with congestive heart failure is markedly increased and often reaches twice the normal size (fig 9) . A typical gross finding of chronic Chagas heart disease is apex effacement of the left ventricle or aneurysm formation. Whenever either of these occurs, a thrombus appears in different stages of organisation. The other site of thrombus formation is the huge right atrium of the Chagas heart. Thrombi at these locations can travel to the brain and the lungs, and are frequent causes of death.
The main microscopic findings always present in a patient with chronic Chagas heart disease are inflammatory infiltrates and target heart cell lyses (fig 10) . These inflammatory infiltrates are formed by macrophages, and small and large lymphocytes that migrate from the dilated lymphatic vessels to the epicardial surfaces. These immune system mononuclear cells invade the heart and produce lyses of parasitefree target heart cells. The finding of T cruzi amastigote nests in heart cells can be detected microscopically in 10-20% of chronic cases. Importantly, in these cases, the parasite's intracellular nests are more often found in areas of the N Investigation of the cause of autoimmunity will be a daunting task. Therefore, the hallmark of the microscopic pathology in Chagas heart disease is the destruction of the target heart cells by immune effector lymphocytes. This microscopic feature defines a minimal rejection unit (fig 11) . The confluence of numerous rejection units signifies chronic Chagas myocarditis. The destroyed heart fibres are gradually replaced by fibrous scars as the inflammation subsides.
Inflammatory cells infiltrate the heart conducting system in the same manner as the contractile myocardium. The intensity of the auto-destructive process varies from one site to another in the heart; whereas some lesions are fresh, others evolve into fibrous scars as the inflammatory process fades away. With ageing, fibrous scars accumulate in the myocardium and can be found in every heart chamber, particularly in the left ventricle during late stage insufficiency. Histochemical analysis of the sympathetic and parasympathetic nerve endings of patients with chronic Chagas disease has shown a low quantity of catecholamines and deficient acetylcholinesterase activity. Both findings are consistent with progressive autonomic denervation. 77 Furthermore, the autonomous intracardiac nervous system in every Chagas Megaoesophagus and megacolon consist of gross dilation of the hollow viscera and thickening of their walls. Such lesions are associated with loss of coordination of the motility of these digestive tube segments. [78] [79] [80] [81] [82] [83] These changes stem from inflammatory infiltrates of the internal and external layers of smooth muscle cells of the digestive tract wall. However, inflammatory lesions particularly affect the parasympathetic neurones within the walls (fig 12) . Neuronal cell depopulation occurs randomly in all segments of the digestive tract, but this is clinically more often evident in the oesophagus and the colon. Usually, a mega syndrome manifests when neurone loss reaches 55% of the units in the intramural parasympathetic ganglia. In some patients, neuronal depopulation can average 76.5% as compared with control neurone counts. 80 The use of nucleic acid tests has shown the persistence of remnants of T cruzi DNA in tissue samples taken from mega lesions. 83 Although the parasite persists in tissues showing mega syndromes, the literature does not document colonisation of neurones by T cruzi. As neurotoxin release by the parasite has not been shown, it is presumed that neuronolysis and depopulation are not associated with parasitism of these target cells. In contrast, neuronolysis has been associated with adherence of immune system mononuclear cells, as described for a minimal rejection unit. These observations suggest the rejection unit is the common denominator of Chagas disease pathology.
TREATMENT Nifurtimox (4-(5-nitro-furylidenoamine)-tetrahydro-4-4-1,4-thiazine-1-1-dioxode) and o-benznidazole (N-benzyl-2-nitroimidazolacetamide) are anti-trypanosome drugs used to treat the T cruzi infections. 84 85 The cytotoxic and genotoxic effects associated with the drugs are related to their chemical structures, resulting in the release of electrophilic radicals on enzymatic nitro-reduction. The free radicals have been identified as the nitro-anion, H 2 , K O 2 and hydrogen peroxide. [86] [87] [88] [89] [90] Drug toxicity affects the parasite and also any other innocent bystander cells in the human body. 85 The nitrogroup reduction alters the number of electrons at the external orbital, thus augmenting the mutagenic potential because free radicals bind to DNA double strands, forming adducts. [85] [86] [87] [88] [89] [90] The use of nitroderivatives in the treatment of acute Chagas disease has had limited success. [91] [92] [93] [94] [95] [96] Physicians have used these drugs sparingly because they do not eradicate T cruzi infections in 83.5% of acute cases. Further, an indirect indication of parasite persistence is provided by positive aftertreatment immunological tests. These observations explain why caution is required before using these drugs, in addition to reports showing that the use of anti-trypanosome nitroderivatives does not halt progression of the disease in patients treated for Chagas disease. 27 For example, electrocardiographic changes in patients treated for Chagas disease did not differ statistically from those recorded in a placebotreated cohort of patients with acute Chagas disease. 27 Furthermore, chagasic changes on electrocardiogram have been recorded in patients 24 years after treatment with a nitroderivative compound. [94] [95] [96] Moreover, in patients acutely Figure 11 The ''minimal rejection unit'' in the skeletal muscle of a patient with Chagas disease. Note the immune system mononuclear cell palisade of the target cell sarcolemma and concomitant lyses of the myofibres in the absence of parasite colonies in situ. infected with T cruzi, heart biopsies showed myocarditis, 97 even though the patients had been treated with a nitroderivative drug. These findings strongly suggest that nitroderivative drug treatment does not prevent the onset of severe heart lesions. In the chronic indeterminate phase, the only acceptable criterion for cure resulting from specific drug therapy for T cruzi infections is the lack of detectable specific antibodies and the results of nucleic acid tests to determine evidence of the parasite's phenotype and genotype. Results of these studies showed that 94.7% of nitroderivative drug-treated patients with chronic Chagas disease tested positive for specific antibodies to T cruzi antigens. 93 In one series that had reported 76% success in the treatment of patients with chronic Chagas disease with a nitroderivative compound, a mere 8% drop was observed in the prevalence of positive nucleic acid tests 6-18 years after chemotherapy. Importantly, it was shown that mortality was similar in treated and untreated groups of patients with chronic Chagas disease 10 years after chemotherapy. 27 
CONCLUSIONS
Drug treatment for T cruzi infections is considered unsatisfactory because it does not halt the progressive lesions of the heart and digestive tract of patients with chronic Chagas disease. It appears that effective treatment of Chagas disease would require a drug that does not produce undesirable effects and eradicates the infection or improves the prognosis of a sick patient. Specific chemotherapy with the drugs that are now available may not be cost effective. Nevertheless, treatment with a nitroderivative compound is clearly indicated in acutely infected patients, during the course of immune suppression and during organ transplantation of a patient with Chagas disease.
The controversy over the efficacy of treatment underlines the importance of sustained therapeutic research to control Chagas disease. 2 The results of studies reported here suggest that the pathogenesis of the disease is related to kDNA mutations of the vertebrate host's genome. There is a vast field of research on which to base the development of drugs to prevent T cruziinduced kDNA mutations. 3 The persistence of lifelong infections providing a source of kDNA that may result in cumulative mutations over time requries newly developed, targeted drugs. This is an area of scientific research that has the potential to generate health benefits for millions of people already infected with T cruzi, one third of whom will develop clinical manifestations of Chagas disease.
SELF ASSESSMENT QUESTIONS (TRUE (T) FALSE (F); ANSWERS AT THE END OF THE REFERENCES)
1. Acute Chagas disease 
